For patients with fluid overload, only FUROSCIX is FDA-approved to deliver subcutaneous, IV-equivalent* treatment at home.
*based on similar systemic exposure and diuresis
References: 1. Andre AD, Mohr J, Cornelius B, et al. 2020. Successful validation of a wearable, on-body infusor for subcutaneous administration of Furoscix® in heart failure patients, caregivers, and health care practitioners. [Poster]. The HFSA Virtual Annual Scientific Meeting, September 30 – October 6, 2020.